Vertex Announces Fda Clearance Of Investigational New Drug Application For Vx-264
Vertex Pharmaceuticals Incorporated Announced That The U.S. Food And Drug Administration (Fda) Has Cleared The Investigational New Drug Application (Ind) For Vx-264, A Stem Cell-Derived, Fully Differentiated Pancreatic Islet Cell Therapy Encapsulated Into A Vertex-Developed, Immunoprotective Device With The Potential To Treat Type 1 Diabetes (T1D). The Vx-264 Programme Does Not Require The Use Of Immunosuppression, Which May Broaden The Population Of People With T1D That This Investigational Therapy Could Reach.Vx-264 Is An Investigational Cell Therapy In Which Allogeneic Human Stem Cell-Derived Islets Are Encapsulated In A Channel Array Device Designed To Shield The Cells From The Body
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
